- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06071143
KDSTEM주사의 안전성 및 유효성 만성 신장 질환 환자
만성 신장질환 환자를 대상으로 자가 소변 유래 줄기세포 『KDSTEM 주』의 안전성, 내약성 및 예비 유효성을 평가하기 위한 단일군, 공개 라벨, 용량 증량, 단일기관, 1상 연구
A Single arm, Open-labelled, Dose-escalation, Single-center, Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Autologous Urine-derived Stem Cells, 『KDSTEM Inj.』, in Patients with Chronic Kidney Disease.
The aim of this study is to evaluate the safety and preliminary efficacy of KDSTEM Inj. in the treatment in Patients with Chronic Kidney Disease.
연구 개요
상세 설명
This clinical trial is a single-arm, open-labelled, dose-escalation, single-center Phase 1 study. Its aim is to evaluate the safety, tolerability, and preliminary efficacy of autologous urine-derived stem cells in patients with Chronic Kidney Disease.
If subjects voluntarily sign a written agreement to participate in this clinical trial, the subjects shall undergo the necessary examinations, as outlined in the clinical trial protocol, approximately one month prior to the administration of the investigational product.
After assessing the suitability of the subjects and ensuring participants meet the inclusion/exclusion criteria, eligible subjects will be assigned to different treatment arms. Subjects determined eligible by the investigator for receiving the investigational product on the scheduled administration day will receive a intravenous dose of the investigational product in visit 2, visit 3, and visit 4.
Safety and Efficacy assessments are conducted at 4, 8, 12, 16, 20, and 24 weeks after from the first administration to last administration of the investigational product, spanning a total of 24 weeks.
After all the subjects have completed visit 10, Safety and Efficacy will be analyzed.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
Chungcheongnam-do
-
Daejeon, Chungcheongnam-do, 대한민국
- Chungnam National University Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female aged between 19 and 80 at the time of signing the agreement
- Chronic kidney disease patients with an eGFR of 20 to 59 ml/min/1.73m² by MDRD at the screening and baseline
- Male or female of childbearing age agreed to use accurate birth control method during this clinical trial
- Subjects voluntarily signed an agreement in writing for this clinical trial
Exclusion Criteria:
-
Subjects who meet any of the following conditions at the screening visit
- Systemic infection
- HIV, HBV, HCV, Syphilis (+)
- Blood pressure higher than 190mmHg of SBP or 110mmHg of DBP
- AST or ALT higher than 3 times the upper limit of normal values
-
Subjects who received hemodialysis within 12 weeks prior to the screening or will be receive hemodialysis during this clinical trial
-
Subjects who received kidney transplantation or will be receive kidney transplantation during this clinical trial
-
Subjects diagnosed with the following diseases
- Solid Tumors or Hematologic Malignancies within 5 years prior to the screening
- Cognitive disorder, Alzheimer's disease or mental illness be clinically significant.
- Alcohol or drug abuse
- Severe Respiratory disease (Chronic Obstructive Pulmonary Disease, asthma, pneumonia, pulmonary embolism and pneumothorax, etc.)
- Stroke
- Heart related diseases (within 3 months prior to the screening severe cardiovascular conditions (angina Pectoris, myocardial infarction, unstable arrhythmia, heart failure, etc.)
-
Subjects who received cell therapy or another clinical trial product/device within 4 weeks prior to the screening
-
Subjects who were hypersensitivity reaction pertaining to penicillin, streptomycin, and amphotericin B
-
Subjects, as determined by an investigator, receiving treatment anticipated to affect the results of the clinical trials
-
Subjects being pregnant, providing breast milk, resulted in positive pregnancy test at screening or planning for pregnancy during this clinical trial
-
etc. Subjects determined unsuitable for this clinical trial by the investigator
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: KDSTEM Inj.
|
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
The number of subjects with treatment-related adverse events as assessed by CTCAE version 5.0
기간: 28 weeks follow-up after first injection
|
vital sign, laboratory findings, physical exam, chest x-ray, cardiography, adverse drug reactions |
28 weeks follow-up after first injection
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
eGFR
기간: From the first injection until 28 weeks later
|
The variation in eGFR at each measurement compared to baseline measurement. |
From the first injection until 28 weeks later
|
|
BUN
기간: From the first injection until 28 weeks later
|
The variation in BUN at each measurement compared to baseline measurement. |
From the first injection until 28 weeks later
|
|
Serum creatinine
기간: From the first injection until 28 weeks later
|
The variation in Serum creatinine at each measurement compared to baseline measurement. |
From the first injection until 28 weeks later
|
|
UPCR
기간: From the first injection until 28 weeks later
|
The variation and the rate of Change in UPCR at Each measurement compared to baseline measurement. |
From the first injection until 28 weeks later
|
|
UACR
기간: From the first injection until 28 weeks later
|
The variation and the rate of Change in UACR at Each measurement compared to baseline measurement. |
From the first injection until 28 weeks later
|
|
NGAL(Neutrophil Gelatinase Associated Lipocalin)
기간: The first administration time, 4 weeks and 24 weeks after the third administration.
|
Changes in NGAL (urine) and NGAL (plasma) at 4 weeks, 24 weeks measurement time after third injection compared to baseline |
The first administration time, 4 weeks and 24 weeks after the third administration.
|
|
IL-6, IL-8, CCL18, TNF-α, α-Klotho
기간: The first administration time, 4 weeks and 24 weeks after the third administration.
|
Changes in IL-6, IL-8, CCL18, TNF-α, α-Klotho at 4 weeks, 24 weeks measurement time after third injection compared to baseline |
The first administration time, 4 weeks and 24 weeks after the third administration.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Dae-Eun Choi, M.D, Ph.D, Chungnam National University Hospital
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
- KD-CP-22-1
- 101473 (기타 보조금/기금 번호: Republic of Korea Ministry of Food and Durg Safety)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .